A Pilot Study of Nemolizumab Injections to Treat Lichen Planopilaris
A Condition Causing Scalp Hair Loss and Itching
Phase 4, Open-Label Treatment Study
Led by The Skin Center Dermatology Group · Updated on 2026-02-10
10
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Lichen planopilaris LPP is a type of scarring hair loss caused by inflammation, leading to permanent hair loss and uncomfortable scalp symptoms like itching and burning. Current treatments often dont work well and can have side effects, so new targeted options are needed. Nemolizumab, a drug that blocks the IL-31 receptor and is approved for other itchy skin conditions, is being studied as a potential treatment for LPP in this phase 4 pilot study.
Participants in the study will receive nemolizumab through subcutaneous injections every 4 weeks, with doses adjusted based on weight. This is a noncontrolled study, meaning all participants receive nemolizumab without comparison to a placebo or other treatment. The study will last at least 24 weeks, during which participants will be monitored for changes in their LPP symptoms.
During the study, participants will have their hair loss and scalp condition assessed using specific scoring systems, including the Lichen Planopilaris Activity Index and the Investigator Global Assessment for scarring alopecia. They will also report on scalp itching using a numerical rating scale. Optional scalp biopsies may be performed for research. Safety and treatment effects will be followed over the 24-week period, with all assessments designed to understand how nemolizumab influences LPP activity and symptoms.
CONDITIONS
Brief Title
Nemolizumab to Treat Lichen Planopilaris, a Noncontrolled, Prospective, Pilot Study.
Research Team
P
Peter Friedman, MD PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
Nemolizumab injections (study group)
Topical or systemic guideline-recommended therapies
What it is
Nemolizumab is a monoclonal antibody targeting the interleukin-31 receptor, administered as subcutaneous injections every 4 weeks, evaluated in adults with active lichen planopilaris (LPP) and scalp pruritus.
Guideline-recommended therapy for adults with LPP includes topical or intralesional corticosteroids, oral antimalarials (such as hydroxychloroquine), and systemic immunomodulatory agents like methotrexate or cyclosporine.
Role in study
Evaluated as the sole intervention in this open-label, prospective pilot study for LPP.
Represents established frontline and additional current-care options for similar patients outside of clinical trials.
Primary use
Investigated for reducing scalp inflammation, pruritus, and disease activity in LPP.
Used to control inflammation, reduce symptoms like pruritus, and stabilize or slow disease progression in LPP.
How it is given or performed
Subcutaneous injection of nemolizumab every 4 weeks, with dose based on body weight, administered by healthcare professionals.
Topical corticosteroids or calcineurin inhibitors applied directly to affected scalp. Oral medications such as hydroxychloroquine, methotrexate, or cyclosporine taken as prescribed. Intralesional corticosteroids injected by clinicians when indicated.
Evidence status
Evidence is limited to this ongoing pilot study. Larger studies are needed to determine effectiveness and safety for LPP.
Supported by clinical guidelines, controlled trials, and systematic reviews evaluating their effectiveness in reducing inflammation and symptoms in LPP, with varying degrees of evidence for individual agents.
Important limitations
Limitations include a small sample size, absence of a control arm, short follow-up, and limited available experience with nemolizumab for LPP.
Responses to current therapies can be highly variable. Some medications are used off-label for LPP, with adverse effects or relapse sometimes limiting long-term use.
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
Age 18 years or older
Clinical and/or histopathologic diagnosis of lichen planopilaris
Presence of scalp itching (pruritus)
Average Peak Pruritus Numerical Rating Scale score of 4 or higher in the 7 days before Day 1
Ability and willingness to provide written informed consent and comply with study procedures
Willingness to undergo optional scalp biopsy for research purposes
You will not qualify if you...
Other forms of alopecia that could interfere with study assessments
Any systemic disease associated with hair loss
Inflammatory or infectious scalp diseases that may interfere with the study
Other conditions causing itching (pruritus)
Prior use of nemolizumab
Current treatment with systemic or topical JAK inhibitors or biologics without a 12-week washout
Current treatment with DMARDs without a 12-week washout
Prior treatment failure of scarring alopecia with systemic or topical JAK inhibitors or biologics
Current treatment with topical or intralesional corticosteroids without a 4-week washout
Current treatment with other hair loss therapies unless stable for 6 months or 3 months washout completed
Allergy or hypersensitivity to nemolizumab or its ingredients
Pregnancy or unwillingness to use highly effective contraception
Any medical condition that may interfere with participation or study results as judged by the investigator
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 24 weeks
Participants receive subcutaneous injections of Nemolizumab every 4 weeks with weight-based dosing to treat Lichen Planopilaris.
6 visits (in-person) every 4 weeks
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Efficacy, safety, tolerability, and satisfaction of N-acetylcysteine and pentoxifylline in lichen planopilaris patients under treatment with topical clobetasol: A triple arm blinded randomized controlled trial.